Analytical Data
-
Gene name
PDCD1
- Application
-
Alternative Names
PDCD1；PD1；Programmed cell death Protein 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15116
-
Expression Region
25-167aa
-
AA Sequence
LDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQ
-
Molecular Weight
18.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PDCD1, commonly known as Programmed Cell Death Protein 1 (PD-1), is an immune checkpoint receptor that plays a crucial role in regulating immune responses and maintaining self-tolerance. High expression levels of PD-1 are found on activated T cells, B cells, and myeloid cells, and its interaction with its ligands, PD-L1 and PD-L2, can lead to the inhibition of T cell activation and proliferation. This mechanism is significant in the context of cancer, as many tumors exploit the PD-1/PD-L1 pathway to evade immune surveillance, making PDCD1 a prominent target for cancer immunotherapy. The development of PDCD1 recombinant proteins has allowed researchers to investigate the structural and functional properties of PD-1, facilitating the discovery of novel inhibitors that can block this pathway. Various studies have demonstrated that engineered antibodies and fusion proteins targeting PD-1 can enhance anti-tumor immunity, leading to significant clinical benefits in cancer patients. Additionally, understanding the molecular basis of PD-1 signaling can provide insights into autoimmune diseases, where PD-1 dysfunction is often implicated. As a result, PDCD1 recombinant proteins serve as valuable tools in both basic research and therapeutic applications, driving advancements in the fields of immunology and oncology.
